Search

The article presents a case study of a contact dermatitis caused by diltiazem cream and cross-reactivity with other calcium channel blockers. Topics include a 47-year-old healthy man, without a history of atopic disease, experienced a generalized papular rash starting from the anogenital area, and he developed an eczematous eruption in the anogenital area, and this was followed by rapid dissemination of the skin lesions to the trunk and extremities.

In humans, pruritus (itch) is a common but poorly understood symptom in numerous skin and systemic diseases. Endothelin 1 (ET-1) evokes histamine-independent pruritus in mammals through activation of its cognate G protein-coupled receptor endothelin A receptor (ETAR). Here, we have identified neural endothelin-converting enzyme 1 (ECE-1) as a key regulator of ET-1-induced pruritus and neural signaling of itch. We show here that ETAR, ET-1, and ECE-1 are expressed and colocalize in murine dorsal root ganglia (DRG) neurons and human skin nerves. In murine DRG neurons, ET-1 induced internalization of ETAR within ECE-1-containing endosomes. ECE-1 inhibition slowed ETAR recycling yet prolonged ET-1-induced activation of ERK1/2, but not p38. In a murine itch model, ET-1-induced scratching behavior was substantially augmented by pharmacological ECE-1 inhibition and abrogated by treatment with an ERK1/2 inhibitor. Using iontophoresis, we demonstrated that ET-1 is a potent, partially histamine-independent pruritogen in humans. Immunohistochemical evaluation of skin from prurigo nodularis patients confirmed an upregulation of the ET-1/ETAR/ECE-1/ERK1/2 axis in patients with chronic itch. Together, our data identify the neural peptidase ECE-1 as a negative regulator of itch on sensory nerves by directly regulating ET-1-induced pruritus in humans and mice. Furthermore, these results implicate the ET-1/ECE-1/ERK1/2 pathway as a therapeutic target to treat pruritus in humans. [ABSTRACT FROM AUTHOR]

In humans, pruritus (itch) is a common but poorly understood symptom in numerous skin and systemic diseases. Endothelin 1 (ET-1) evokes histamine-independent pruritus in mammals through activation of its cognate G protein--coupled receptor endothelin A receptor (ETAR). Here, we have identified neural endothelin--converting enzyme 1 (ECE-1) as a key regulator of ET-1--induced pruritus and neural signaling of itch. We show here that ETAR, ET-1, and ECE-1 are expressed and colocalize in murine dorsal root ganglia (DRG) neurons and human skin nerves. In murine DRG neurons, ET-1 induced internalization of ETAR within ECE-1--containing endosomes. ECE-1 inhibition slowed ETAR recycling yet prolonged ET-1--induced activation of ERK1/2, but not p38. In a murine itch model, ET-1--induced scratching behavior was substantially augmented by pharmacological ECE-1 inhibition and abrogated by treatment with an ERK1/2 inhibitor. Using iontophoresis, we demonstrated that ET-1 is a potent, partially histamine-independent pruritogen in humans. Immunohistochemical evaluation of skin from prurigo nodularis patients confirmed an upregulation of the ET-1/ETAR/ECE-1/ERK1/2 axis in patients with chronic itch. Together, our data identify the neural peptidase ECE-1 as a negative regulator of itch on sensory nerves by directly regulating ET-1--induced pruritus in humans and mice. Furthermore, these results implicate the ET-1/ECE-1/ERK1/2 pathway as a therapeutic target to treat pruritus in humans. [ABSTRACT FROM AUTHOR]

The article discusses the clinical and immunological effects of subsequent granulocyte colony-stimulating factor (G-CSF) and ruxolitinib therapy in a chronic mucocutaneous candidiasis (CMC) patient. It states that G-CSF lacks the immunological and clinical response. It mentions that ruxolitinib shows continuous amelioration of CMC over months.

The article presents a case study of 55-year-old White non-atopic metalworker with the medical history of work-related hand eczema. It notes the allergic contact dermatitis caused by the emulsifying agent 2-Amino-2-methyl-1-propanol (AMP), which is used in metalworking fluids (MWF), and AMP used in cosmetics like hair dyes.

The article presents the case study of 31-year-old non-atopic toolmaker being exposed to a concentrated solution with an oligomeric reaction product, with diphenylmethane and tripropyleneglycol. It states that the patient wore protective gloves and goggles, his right forearm and face that were contaminated. It focuses application of topical corticosteroids in the affected are.

The article discusses research which patch tested didecyldimethylammonium chloride (DDAC) in patients with suspected contact sensitization to surface or instrument disinfectants after observing a case of a geriatric nurse with airborne occupational allergic contact dermatitis caused by DDAC. Topics covered include the clinical relevance of patch testing, test concentrations which shows strong and weak positive reactions, and ideal concentrations for suspected allergic contact dermatitis.

The article offers information on a study related to the concentration of povidone-iodine in patch test. Topics discussed include use of povidone-iodine (PVP-I) as a skin disinfectant in wound care and preparation for surgery; medical examination of suspected allergic contact dermatitis (ACD) caused by antiseptics; and administration of iodine-containing contrast media.

The article discusses on the dermatological problem a 24-year-old man who have a partially ulcerated nodules in the right groin which surrounded by inflammation and oedema. The patients reported had taken the psychoactive stimulant methylenedioxypyrovalerone and experienced a psychotic episode. The article also discusses on the treatment using topical antiseptic but has developed new papules on the left wrist.

An answer to a photo quiz related to the diagnosis of ulcerative mucositis, skin lesions, and nail dystrophy in a 32 year old man published in the periodical is presented.